These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31499391)

  • 1. Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis.
    Lombardo G; Enache D; Gianotti L; Schatzberg AF; Young AH; Pariante CM; Mondelli V
    Psychoneuroendocrinology; 2019 Dec; 110():104420. PubMed ID: 31499391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
    Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
    J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men.
    Mattsson C; Reynolds RM; Simonyte K; Olsson T; Walker BR
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1347-52. PubMed ID: 19141586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
    Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
    J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiglucocorticoid treatments for mood disorders.
    Gallagher P; Malik N; Newham J; Young AH; Ferrier IN; Mackin P
    Cochrane Database Syst Rev; 2008 Jan; (1):CD005168. PubMed ID: 18254070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mifepristone as a therapeutic agent in psychiatry.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2013 Jun; 51(6):11-4. PubMed ID: 23814820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression.
    Schüle C; Baghai TC; Eser D; Rupprecht R
    Expert Rev Neurother; 2009 Jul; 9(7):1005-19. PubMed ID: 19589050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiglucocoticoid treatments for depression.
    Young AH
    Aust N Z J Psychiatry; 2006 May; 40(5):402-5. PubMed ID: 16683965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The glucocorticoid receptor: part of the solution or part of the problem?
    Pariante CM
    J Psychopharmacol; 2006 Jul; 20(4 Suppl):79-84. PubMed ID: 16785275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-trans retinoic acid-induced hypothalamus-pituitary-adrenal hyperactivity involves glucocorticoid receptor dysregulation.
    Hu P; Liu J; Zhao J; Qi XR; Qi CC; Lucassen PJ; Zhou JN
    Transl Psychiatry; 2013 Dec; 3(12):e336. PubMed ID: 24346134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study.
    Buckley T; Duggal V; Schatzberg AF
    J Clin Sleep Med; 2008 Jun; 4(3):235-41. PubMed ID: 18595436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid receptor number and cortisol excretion in mood, anxiety, and psychotic disorders.
    Yehuda R; Boisoneau D; Mason JW; Giller EL
    Biol Psychiatry; 1993 Jul 1-15; 34(1-2):18-25. PubMed ID: 8373936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortisol in mood disorders.
    Young AH
    Stress; 2004 Dec; 7(4):205-8. PubMed ID: 16019585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis.
    Soria V; González-Rodríguez A; Huerta-Ramos E; Usall J; Cobo J; Bioque M; Barbero JD; García-Rizo C; Tost M; Monreal JA; ; Labad J
    Psychoneuroendocrinology; 2018 Jul; 93():8-19. PubMed ID: 29680774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.
    Young AH; Gallagher P; Watson S; Del-Estal D; Owen BM; Ferrier IN
    Neuropsychopharmacology; 2004 Aug; 29(8):1538-45. PubMed ID: 15127079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition.
    Keller J; Gomez R; Williams G; Lembke A; Lazzeroni L; Murphy GM; Schatzberg AF
    Mol Psychiatry; 2017 Apr; 22(4):527-536. PubMed ID: 27528460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.
    Mackin P; Gallagher P; Watson S; Young AH; Ferrier IN
    Aust N Z J Psychiatry; 2007 Apr; 41(4):321-6. PubMed ID: 17464718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients.
    Jokinen J; Nordström P
    J Affect Disord; 2009 Jul; 116(1-2):88-92. PubMed ID: 19054568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression.
    Lembke A; Gomez R; Tenakoon L; Keller J; Cohen G; Williams GH; Kraemer FB; Schatzberg AF
    Psychoneuroendocrinology; 2013 Jan; 38(1):115-21. PubMed ID: 22727477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central and peripheral glucocorticoid receptors are involved in the plasma cortisol response to an acute stressor in rainbow trout.
    Alderman SL; McGuire A; Bernier NJ; Vijayan MM
    Gen Comp Endocrinol; 2012 Mar; 176(1):79-85. PubMed ID: 22233772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.